

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 5 MAY 10 CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 6 MAY 11 KOREAPAT updates resume
NEWS 7 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAplus and
USPATFULL/USPAT2
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/CAplus
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 14 JUL 14 FSTA enhanced with Japanese patents
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:35:18 ON 24 AUG 2006

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:35:24 ON 24 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4
DICTIONARY FILE UPDATES: 23 AUG 2006 HIGHEST RN 904004-64-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10507153.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O, S

Structure attributes must be viewed using STN Express query preparation.

>

s

11

SAMPLE SEARCH INITIATED 12:35:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED

1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 ful
FULL SEARCH INITIATED 12:35:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30 TO ITERATE

100.0% PROCESSED 30 ITERATIONS
SEARCH TIME: 00.00.01

29 ANSWERS

L3 29 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE
FULL ESTIMATED COST ENTRY TOTAL
166.94 SESSION 167.15

FILE 'CAPLUS' ENTERED AT 12:35:56 ON 24 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Aug 2006 VOL 145 ISS 9
FILE LAST UPDATED: 23 Aug 2006 (20060823/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13
L4 3 L3

=> d abs bib hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein Y = 0 (i.e., absent) or -[COCH(CH₃)NH]-; X = O or S; R₁, R₂, R₃, R₄, R₅ = independently H, halo, NO₂, NH₂, OH and derivs., alkyl, alkyl(hydroxy/amino); R', R'' = independently alkyl or alkoxy; Z = alkyl, alkoxy or alkylamino; and their pharmaceutically acceptable salts] were prepared as antitumor agents. For example, (S)-isomeric compound II was prepared, in 52.3% yield, by condensation of 2-ethyl-5-[[4-(3,5-dimethylphenyl)piperazin-1-ylcarbonyl]amino]-6-methoxynicotinic acid dissolved in pyridine with (S)-N-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-2-aminopropanamide (see PCT/KR99/00787) in the presence of DCC/DMAP for 24 h at room temperature. I have comparable or superior

antitumor activities against human solid cancer cell lines compared to cisplatin, and equal or superior activities compared to mitomycin C against P388 mouse cancer cells. For example, II showed ED₅₀ = 0.12 µg/mL against A549 (human non-small lung cell) vs. cisplatin (0.81 µg/mL), and was approx. 3.7-fold more potent than mitomycin C. The LD₅₀ of II was 80 mg/kg i.v., vs. 9.7 mg/kg i.p. for cisplatin.

AN 2003:719452 CAPLUS

DN 139:245913

TI Preparation of 9-aminoacridines as antitumor agents

IN Cho, Eui-hwan; Chung, Sun-gan; Lee, Sun-hwan; Kwon, Ho-seok; Kang, Dong-wook

PA Samjin Pharmaceutical Co., Ltd., S. Korea

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003074490	A1	20030912	WO 2002-KR392	20020307
	W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LT, LU, LV, MA, MD, MG, MK, PT, RO, RU, SD, SE, SG, SI, UG, US, UZ, VN, YU, ZA, ZM, ZW			BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KZ, LC, LK, LR, LS, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,	
	RW: GH, GM, KE, LS, MW, MZ, SD, KG, KZ, MD, RU, TJ, TM, AT, GR, IE, IT, LU, MC, NL, PT, GN, GQ, GW, ML, MR, NE, SN,			SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BE, CH, CY, DE, DK, ES, FI, FR, GB, SE, TR, BF, BJ, CF, CG, CI, CM, GA, TD, TG	
	CA 2478302	AA	20030912	CA 2002-2478302	20020307
	AU 2002235040	A1	20030916	AU 2002-235040	20020307
	EP 1487799	A1	20041222	EP 2002-701809	20020307
	R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK,			GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR	
	CN 1622939	A	20050601	CN 2002-828490	20020307
	JP 2005523296	T2	20050804	JP 2003-572959	20020307
	NZ 535791	A	20051125	NZ 2002-535791	20020307
	RU 2269524	C2	20060210	RU 2004-129745	20020307
	US 2005222167	A1	20051006	US 2004-507153	20040907
PRAI	WO 2002-KR392	W	20020307		
OS	MARPAT 139:245913				
IT	537048-98-9P, (S)-4-(3,5-Dimethylphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-66-0P, (S)-4-(3,5-Dimethoxyphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide				
	RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(antitumor agent; preparation of aminoacridines as antitumor agents via condensation)				
RN	537048-98-9 CAPLUS				
CN	1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-66-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 600153-64-8P, (S)-4-Phenylpiperazine-1-carboxylic acid
 N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-68-2P,
 (S)-4-(3,5-Difluorophenyl)piperazine-1-carboxylic acid
 N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-70-6P,
 (S)-4-(3,5-Dichlorophenyl)piperazine-1-carboxylic acid
 N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-72-8P,
 (S)-4-(3-Fluorophenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-74-0P, (S)-4-(3-Hydroxyphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-76-2P, (S)-4-(3,4,5-Trimethoxyphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-78-4P, (S)-4-(3,5-Dimethoxyphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-2-methoxy-6-

propylpyridin-3-yl]amide 600153-80-8P, (S)-4-(3,5-Dimethylphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-2-methoxy-6-propylpyridin-3-yl]amide 600153-82-0P, (S)-N-[1-[3-(Acridin-9-ylamino)-5-hydroxymethylphenylcarbamoyl]ethyl]-5-[[4-(3,5-dimethoxyphenyl)piperazin-1-ylcarbothionyl]amino]-6-methoxy-2-methylnicotineamide 600153-84-2P, (S)-N-[1-[3-(Acridin-9-ylamino)-5-hydroxymethylphenylcarbamoyl]ethyl]-5-[[4-(3,5-dimethoxyphenyl)piperazine-1-carbothionyl]amino]-2-ethyl-6-methoxynicotineamide 600153-86-4P, (S)-N-[1-[3-(Acridin-9-ylamino)-5-hydroxymethylphenylcarbamoyl]ethyl]-5-[[4-(3,5-dimethoxyphenyl)piperazine-1-carbothionyl]amino]-6-methoxy-2-propylnicotineamide 600153-88-6P, (S)-N-[1-[3-(Acridin-9-ylamino)-5-hydroxymethylphenylcarbamoyl]ethyl]-5-[[4-(3,5-dimethylphenyl)piperazine-1-carbothionyl]amino]-2-ethyl-6-methoxynicotineamide 600153-90-0P, (S)-4-(3,5-Dimethylphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(hydroxymethyl)-5-(2-methylacridin-9-ylamino)phenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-91-1P, (S)-4-(3,5-Dimethylphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(3,4-dimethylacridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-1-6-ethyl-2-methoxypyridin-3-yl]amide 600153-92-2P, (S)-4-(3,5-Dimethylphenyl)piperazine-1-carboxylic acid N-[5-[[1-[[3-(4-methoxyacridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]ethyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-93-3P, 4-Phenylpiperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-94-4P, 4-(3,5-Dimethylphenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-95-5P, 4-(3,5-Dimethoxyphenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-96-6P, 4-(3,5-Difluorophenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-97-7P, 4-(3,5-Dichlorophenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-98-8P, 4-(3-Fluorophenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600153-99-9P, 4-(3-Hydroxyphephenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600154-00-5P, 4-(3,4,5-Trimethoxyphenyl)piperazine-1-carboxylic acid N-[5-[[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]carbamoyl]-6-ethyl-2-methoxypyridin-3-yl]amide 600154-01-6P, N-[3-(Acridin-9-ylamino)-5-hydroxymethylphenyl]-5-[[4-(3,5-dimethoxyphenyl)piperazin-1-ylcarbothionyl]amino]-2-ethyl-6-methoxynicotineamide 600154-02-7P, N-[3-(Acridin-9-ylamino)-5-hydroxymethylphenyl]-5-[[4-(3,5-dimethylphenyl)piperazin-1-ylcarbothionyl]amino]-2-ethyl-6-methoxynicotineamide 600154-03-8P, N-[3-(Acridin-9-ylamino)-5-hydroxymethylphenyl]-5-[[4-(3-fluorophenyl)piperazine-1-carbothionyl]amino]-2-ethyl-6-methoxynicotineamide 600154-05-0P, N-[3-(Acridin-9-ylamino)-5-hydroxymethylphenyl]-5-[[4-(3,5-dichlorophenyl)piperazine-1-carbothionyl]amino]-2-ethyl-6-methoxynicotineamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(antitumor agent; preparation of aminoacridines as antitumor agents via

condensation)

RN 600153-64-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 600153-68-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-70-6 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-72-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-74-0 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-76-2 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-78-4 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2-methoxy-6-propyl-3-pyridinyl]-4-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-80-8 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2-methoxy-6-propyl-3-pyridinyl]-4-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-82-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]-5-[[[4-(3,5-dimethoxyphenyl)-1-piperazinyl]thioxomethyl]amino]-2-methoxy-6-methyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-84-2 CAPLUS


CN 3-Pyridinecarboxamide, N-[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]-5-[[[4-(3,5-dimethoxyphenyl)-1-piperazinyl]thioxomethyl]amino]-6-ethyl-2-methoxy-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 600153-86-4 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]-5-[[[4-(3,5-dimethoxyphenyl)-1-piperazinyl]thioxomethyl]amino]-2-methoxy-6-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 600153-88-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[(1S)-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]-5-[[[4-(3,5-dimethylphenyl)-1-piperazinyl]thioxomethyl]amino]-6-ethyl-2-methoxy- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-90-0 CAPLUS


CN 1-Piperazinecarboxamide, 4-(3,5-dimethylphenyl)-N-[6-ethyl-5-[(1S)-2-[(3-hydroxymethyl)-5-[(2-methyl-9-acridinyl)amino]phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-2-methoxy-3-pyridinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-91-1 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[(1S)-2-[[3-[(3,4-dimethyl-9-acridinyl)amino]-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 600153-92-2 CAPLUS


CN 1-Piperazinecarboxamide, 4-(3,5-dimethylphenyl)-N-[6-ethyl-5-[(1S)-2-[(3-(hydroxymethyl)-5-[(4-methoxy-9-acridinyl)amino]phenyl)amino]-1-methyl-2-oxoethylamino]carbonyl]-2-methoxy-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 600153-93-3 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600153-94-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600153-95-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600153-96-6 CAPLUS
 CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600153-97-7 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600153-98-8 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600153-99-9 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600154-00-5 CAPLUS
 CN 1-Piperazinecarboxamide, N-[5-[[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600154-01-6 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]-5-[[[4-(3,5-dimethoxyphenyl)-1-piperazinyl]thioxomethyl]amino]-6-ethyl-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600154-02-7 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]-5-[[[4-(3,5-dimethylphenyl)-1-piperazinyl]thioxomethyl]amino]-6-ethyl-2-methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600154-03-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]-6-ethyl-5-[[[4-(3-fluorophenyl)-1-piperazinyl]thioxomethyl]amino]-2-methoxy-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 600154-05-0 CAPLUS
 CN 3-Pyridinecarboxamide, N-[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]-5-
 [[[4-(3,5-dichlorophenyl)-1-piperazinyl]thioxomethyl]amino]-6-ethyl-2-
 methoxy- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 AB This study examined the pharmacokinetic disposition of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, in mice, rats, rabbits and dogs after i.v. administration. The serum concentration-time curves of SJ-8029 were best described by tri-exponential equations in all these animal species. The mean Cl, Vss and t_{1/2} were 0.3 l/h, 0.11 and 63.2 min in mice, 1.5 l/h, 1.61 and 247.7 min in rats, 13.8 l/h, 39.61 and 245.9 min in rabbits, and 29.2 l/h, 44.61 and 117.4 min in dogs, resp. Based on animal data, the pharmacokinetics of SJ-8029 were predicted in humans using simple allometry and also by several species-invariant time transformations using kallynochroon, polysichron and dienetichron times. The human pharmacokinetic parameters of Cl, Vss and t_{1/2} predicted by the simple allometry and various species-invariant time methods were 50.4-145.0 l/h, 369.0-579.81 and 242.0-1448.3 min, resp. These preliminary parameter values may be useful in designing early pharmacokinetic studies of SJ-8029 in humans.
 AN 2003:609358 CAPLUS
 DN 140:35281

TI Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods

AU Shin, Beom S.; Kim, Dong H.; Cho, Chang Y.; Park, Si K.; Chung, Sun G.; Cho, Eui H.; Lee, Sun H.; Joo, Jeong H.; Kwon, Ho S.; Lee, Kang C.; Yoo, Sun D.

CS College of Pharmacy, Sungkyunkwan University, Suwon, 440-746, S. Korea

SO Biopharmaceutics & Drug Disposition (2003), 24(5), 191-197

CODEN: BDDID8; ISSN: 0142-2782

PB John Wiley & Sons Ltd.

DT Journal

LA English

IT 537048-98-9, SJ 8029


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacokinetic scaling of SJ-8029, novel anticancer agent possessing microtubule and topoisomerase inhibiting activities in different species)

BN 537048-98-9 CAPLUS


1-Piperazinecarboxamide, N-[5-[[[1S]-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

AB This report describes a simple and sensitive isocratic high-performance liquid chromatog. with UV detection for the anal. of a novel antineoplastic agent, SJ-8029 in rat serum. The anal. utilized a Merck Lichrocart RP-8 anal. column and a mobile phase consisting of acetonitrile: 0.1% triethylamine in deionized water (55:45, volume/volume). SJ-8029 was extracted from serum by one-step extraction with tert-Bu Me ether. SJ-8029 was eluted at 12.7 min at a mobile phase flow rate of 1 mL/min. The standard curve was linear ($r^2 = 0.9999$) over the concentration range of 5-10,000 ng/mL. The extraction recovery for SJ-8029 was >89.4% and the intra- and inter-day assay variability of SJ-8029 ranged from 3.9-18.8% and 4.5-18.4%, resp. The LOD and LOQ were 1 and 5 ng/mL, resp., using a serum sample volume of 100 μ L. The developed assay method was applied to a pharmacokinetic study after i.v. injection of SJ-8029 to rats at a dose of 8 mg/kg. In addition, the stability of SJ-8029 was assessed in serum as a function of temperature, and the formation of degradation products M1, M2 and M3 was determined by HPLC with fluorescence detection. Further anal. by LC/MS/MS showed that SJ-8029 was degraded in serum to microtubule and topoisomerase inhibiting components.

AN 2002:832228 CAPLUS

DN 139:17016

TI Analysis and stability of a novel anticancer agent, SJ-8029, possessing microtubule and topoisomerase inhibiting activities

AU Cho, Chang Y.; Shin, Beom S.; Kim, Dong H.; Joo, Jeong H.; Kwon, Ho S.; Lee, Sun H.; Park, Si K.; Chung, Sun G.; Cho, Eui H.; Lee, Hye S.; Yoo, Sun D.

CS College of Pharmacy, Sungkyunkwan University, Suwon, 440-746, S. Korea

SO Analytical Letters (2002), 35(13), 2133-2143

CODEN: ANALBP; ISSN: 0003-2719

PB Marcel Dekker, Inc.

DT Journal

LA English

IT 537048-98-9, SJ 8029


RL: ANT (Analyte); PKT (Pharmacokinetics); ANST (Analytical study); BIOL (Biological study)
(anal. and pharmacokinetics of SJ-8029 in rat serum using HPLC)

RN 537048-98-9 CAPLUS


CN 1-Piperazinecarboxamide, N-[5-[[[1S]-2-[[3-(9-acridinylamino)-5-(hydroxymethyl)phenyl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]-6-ethyl-2-methoxy-3-pyridinyl]-4-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT